All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-08-18T11:00:25.000Z

What are the novel treatment options for patients with relapsed or refractory WM?

Aug 18, 2023
Share:
Learning objective: On behalf of the IWMF, the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on novel treatment options for patients with R/R WM?

Bookmark this article

On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on, What are the novel treatment options for patients with relapsed or refractory Waldenstrom's Macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.

What are the novel treatment options for patients with relapsed or refractory WM?

Buske begins by explaining how chemotherapy-free approaches could be the future of WM treatment and highlights the important role of Bruton’s tyrosine kinase inhibitors. The current structure of clinical trials is discussed, focusing on what patients would want regarding effectiveness, duration of the trial, and limiting exposure to side effects. The panel describes the possible use of immunotherapy vaccines, though these are limited due to burden of disease where they might not be as effective. Finally, Castillo discusses the potential of Bruton’s tyrosine kinase inhibitions, in combination with targeted agents, such as BCL-2 inhibitors, as well as the use of antibody conjugates in the future treatment of WM.

'The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.

This initiative is funded by Cellectar Biosciences, BeiGene and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox